http://www.xconomy.com/seattle/2012/03/06/oncothyreon-shares-tumb...

http://www.xconomy.com/seattle/2012/03/06/oncothyreon-shares-tumble-on-lung-cancer-study-speculation/

HOWEVER from this report...

http://www.primabiomed.com.au/investor/analyst_reports_pdf/100511_National_Securities_Research_Report.pdf

Notice how National Securities has made a point of differentiating between the PRR approach and the Oncothyreon approach and how they think PRR's is superior. This report was from May 2010.

Looks like they may have been right :)


"Although Prima BioMed’s CVac targets the same antigen as Oncothyreon, the technology and
process used is similar to Dendreon’s process for Provenge. In preparing CVac and Provenge,
the patient’s dendritic cells are treated ex vivo with the antigen and the activated dendritic cells
are administered. This is likely more effective than direct administration of the antigen, which
permits less opportunity for the antigen to engage the immune system. Oncothyreon/Merck KGaA
are using a liposomal formulation of MUC-1 which is directly administered. Transgene is also
initiating a Phase 3 trial of a MUC-1 vaccine administered in a viral vector. We are not
enthusiastic about the prospects for direct administration of MUC-1, but believe an activated
dendritic cell therapy will be successful."